What the full archive includes
The archive contains 114,589 published rows, grouped into 113,773 report groups. Each group receives a price based on the recorded test, using laboratory menus or a clearly labelled estimate where its rate is missing. Grouping brings related source rows together; it does not prove that every group represents a separate physical test.
The distinction between the full archive and peptide testing matters. NAD+, small molecules, steroid hormones and other non-peptide labels also appear in the database. They should not all be described as peptide tests.
| Archive category | Report groups | Central estimate, USD |
|---|---|---|
| Named peptides and proteins | 94,723 | $22,682,352.50 |
| Named non-peptides | 12,727 | $3,284,585 |
| Unresolved labels | 4,987 | $1,202,757.50 |
| Unspecified peptide labels | 760 | $190,987.50 |
| Peptide labels with unresolved components | 515 | $108,880 |
| Mixed peptide/non-peptide labels | 61 | $12,700 |
Classification follows the recorded labels, not a fresh authentication of every certificate. Unspecified, mixed and unresolved labels remain visible. The archive includes unresolved seller attribution, so it is not a verified census of grey-market transactions.
Where the $27.48 million comes from
We checked public menus from nine named laboratories: Janoshik, Freedom Diagnostics, Chromate, Vanguard, ILS, TrustPointe, Peptide Test, Kovera and Bioviridian. Other laboratory labels and anonymous codes remain in the calculation.
| Pricing basis | Report groups | Central estimate, USD |
|---|---|---|
| Named-lab menu match | 82,817 | $19,291,205 |
| Named-lab broad-panel assumption | 530 | $129,040 |
| Estimated price from comparable services | 30,426 | $8,062,017.50 |
| Full archive | 113,773 | $27,482,262.50 |
A named-lab match uses that lab’s advertised compound or service price. A broad-panel assumption uses its general service menu where acceptance and exact historical scope are not fully established. Neither confirms what a particular customer ordered or paid.
For the 30,426 groups without a usable original-lab rate, the central estimate uses the median of available lab-price analogues. We prefer the same compound and recorded service. Where that cannot be established, we use a clearly labelled generic analytical-service estimate. Each lab gets one vote, so a large menu does not dominate the median.
Substituting the lowest and highest available analogue prices changes the full-archive result from $25.15 million to $31.54 million. This changes only the rates we had to estimate. It is not a confidence interval, a spending floor or a spending ceiling. Laboratory methods and panel scope differ.
Download every grouped count-by-rate calculation or the category and laboratory totals. The calculation includes the pricing basis and source URLs for each cell.
Retatrutide accounts for $4.78 million
Retatrutide accounts for 19,186 report groups and $4.78 million at current prices. Tirzepatide follows at $3.13 million. The chart plots the five largest totals; the table also includes BPC-157, semaglutide and TB-500.

| Peptide label | Report groups | Central estimate, USD |
|---|---|---|
| Retatrutide | 19,186 | $4,778,095 |
| Tirzepatide | 12,118 | $3,130,467.50 |
| GHK-Cu | 4,855 | $1,134,057.50 |
| Tesamorelin | 4,759 | $1,112,337.50 |
| MOTS-C | 4,287 | $1,080,482.50 |
| BPC-157 | 4,611 | $1,005,252.50 |
| Semaglutide | 2,362 | $618,110 |
| TB-500 | 2,350 | $514,955 |
Each row counts report groups labelled with that compound alone. Blends, mixed labels and reports naming additional components have their own rows in the download. A group is not necessarily a unique batch or physical test.
Match the price to what the certificate measures
The Janoshik peptide menu lists $360 for its common GLP-1 blind test and $215 for BPC-157. The Freedom intake lists $200 for identity with purity where available, $25 for measured content and $175 for endotoxin. Those are different services.
That distinction matters in this archive. Freedom certificates include purity, identity, endotoxin and excipient categories. An endotoxin certificate does not become a $225 base peptide test just because a copied quantity field is present. Unknown excipient pricing receives a labelled estimate rather than a fabricated menu match.
Chromate publishes compound-specific rates. Vanguard and ILS list packages. TrustPointe, Peptide Test, Kovera and Bioviridian extend the rate evidence. A shared service label does not guarantee the same identity method or contamination test.
Each lab’s current tests and published prices, with the date we checked them, are on Choose a lab to test your peptides. Our guide to getting a peptide tested explains which test answers which question. Confirm compound acceptance, form and current quote with the laboratory before commissioning work.
Certificates still do not tell us the bill
Janoshik lists an additional-client report at $50 alongside its $360 GLP-1 analysis. An illustrative order with one analysis and one extra certificate totals $410. Counting both as new $360 tests gives $720. Neither amount is a measured order from our archive.
Freedom’s submission system also distinguishes extra-company certificates from new tests. Names and lot labels can change on a reissued certificate. Removing identical files does not resolve every shared physical analysis.
The model does not reconstruct multi-vial order pricing, negotiated discounts, historical invoices, rush fees, shipping or tax. Private testing is outside the archive. It also cannot price every unrecorded panel. These uncertainties can move actual spending in either direction.
If a vendor says its premium funds testing, useful evidence includes dated orders, the assays purchased, the number of sampled vials and what happened to failed stock. A large COA library establishes a visible testing record; it does not establish the bill or guarantee every vial meets its label. Our retatrutide substitution advisory shows why identity belongs beside purity.
How to reproduce the estimate
Archive and price snapshot: October 7, 2026. Historical records are valued at current menu prices, not the prices in effect when each report was issued. This is not annual spending.
Scope update, October 7: The earlier $4.62 million estimate covered only 18,609 selected reports across five peptides and five labs. This revision prices the full archive and separates named peptide/protein records from other and unresolved labels.
Inspect the full population, rate rules and remaining uncertainty
All 114,589 published rows were passed through the existing report-grouping rules. All 113,773 groups are retained exactly once. No five-compound filter, five-lab filter, numeric-purity requirement or reviewed-vendor requirement is applied to the inventory.
Named laboratory menus support 83,347 groups, including 530 broad-panel assumptions. The other 30,426 groups use modelled rates. Formula: one recorded-service menu price or explicit proxy per report group, plus supported explicitly recorded panel components, aggregated without multiplying a blend by its component count.
Primary certificate type takes precedence over incidental copied fields. Extra panels are added when their scope is explicitly recorded and supported by the rate mapping. Generic composite-method descriptions and incidental fields do not automatically add a contamination fee. Unresolved scope uses an explicitly labelled service proxy; it does not establish a complete replacement quote for every assay.
Finnrick is a report publisher and coordinator, not a laboratory rate. Anonymous lab codes stay anonymous and use disclosed peer-price estimates. No secret mapping to a named laboratory is assumed. Generic proxies may use peptide-service anchors for unresolved non-peptide scopes; those records stay in separate categories.
Grouping consolidates all rows without dropping members: 390 groups contain multiple rows, accounting for 816 additional rows. Another 524 groups have unresolved reference collisions and remain flagged. They are not certified unique physical tests. There are 812 groups without report-reference or artifact metadata and 4,907 without one unambiguous recorded date. All remain in the full model. Two recorded dates in 2002 are unverified, so we do not use them to claim a historical start date.
The rate sensitivity range varies proxy prices only. It does not quantify uncertain methods, undiscovered reissues, copied certificates, missing panels, multi-vial pricing or negotiated bills. Both the central estimate and range are current-price scenarios, not audited expenditure.
Prepared by TitrateLab Research Desk, reviewed October 7, 2026, with AI assistance for source collection, calculation and drafting. See our evidence methodology, the full calculation or submit a correction.